Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial
Jeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, Ighovwerha Ofotokun, Lumine H Na, Catherine Godfrey, Daniel R Kuritzkes, Manish Sagar, Todd T Brown, Susan E Cohn, Grace A McComsey, Francesca Aweeka, Carl J Fichtenbaum, Rachel M Presti, Susan L Koletar, David W Haas, Kristine B Patterson, Constance A Benson, Bryan P Baugh, Randi Y Leavitt, James F Rooney, Daniel Seekins, Judith S Currier, ACTG A5257 Team, George Bishopric, Carmen M Irizarry, Michael M Lederman, Rita Patel, Susan Pedersen, Lynette Purdue, Thuy Tran, Jeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, Ighovwerha Ofotokun, Lumine H Na, Catherine Godfrey, Daniel R Kuritzkes, Manish Sagar, Todd T Brown, Susan E Cohn, Grace A McComsey, Francesca Aweeka, Carl J Fichtenbaum, Rachel M Presti, Susan L Koletar, David W Haas, Kristine B Patterson, Constance A Benson, Bryan P Baugh, Randi Y Leavitt, James F Rooney, Daniel Seekins, Judith S Currier, ACTG A5257 Team, George Bishopric, Carmen M Irizarry, Michael M Lederman, Rita Patel, Susan Pedersen, Lynette Purdue, Thuy Tran
Abstract
Background: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons.
Objective: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability.
Design: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. (ClinicalTrials.gov: NCT00811954).
Setting: 57 sites in the United States and Puerto Rico.
Patients: Treatment-naive persons aged 18 years or older with HIV-1 RNA levels greater than 1000 copies/mL without resistance to nucleoside reverse transcriptase inhibitors or protease inhibitors.
Intervention: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.
Measurements: Virologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 weeks and before 24 weeks or greater than 200 copies/mL at or after 24 weeks, and tolerability failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity. A secondary end point was a combination of virologic efficacy and tolerability.
Results: Among 1809 participants, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence within a margin of equivalence defined as -10% to 10%. Raltegravir and ritonavir-boosted darunavir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence of tolerability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily because of hyperbilirubinemia. For combined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both protease inhibitors. Antiretroviral resistance at the time of virologic failure was rare but more frequent with raltegravir.
Limitation: The trial was open-label, and ritonavir was not provided.
Conclusion: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen.
Primary funding source: National Institute of Allergy and Infectious Diseases.
Figures
Source: PubMed